Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DUW81M
|
|||
| Drug Name |
Tarloxotinib
|
|||
| Synonyms |
Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | |
| Company |
Rain Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H24BrClN9O3+
|
|||
| Canonical SMILES |
CN1C=NC(=C1C[N+](C)(C)CC=CC(=O)NC2=NC=C3C(=C2)C(=NC=N3)NC4=CC(=C(C=C4)Cl)Br)[N+](=O)[O-]
|
|||
| InChI |
1S/C24H23BrClN9O3/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36)/p+1/b5-4+
|
|||
| InChIKey |
MUJMYVFVAWFUJL-SNAWJCMRSA-O
|
|||
| CAS Number |
CAS 1636938-13-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02454842) Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC (TH-4000). U.S. National Institutes of Health. | |||
| REF 2 | Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.